The estimated effectiveness of the vaccine was higher (80%) in babies in a catch-up group.
Though KP.3.1.1 variant levels continue to rise, the proportion of XEC viruses is also trending upward.
Maternal RSV vaccination coverage was 32.6%, and of those 54.1% reported receiving the vaccine at an obstetrician or gynecologist’s office.
Wastewater levels for COVID-19 remain high but are low for RSV and influenza.
Among adults for whom RSV vaccines are recommended, 21% say they will definitely get vaccinated this upcoming season.
Among symptomatic infants, 44% had lower respiratory tract infections.
Decisions about investing in building wastewater surveillance capacity should consider the vast economic and social cost of responding to infectious diseases not detected and arrested early, the authors say.
In one study, nirsevimab was associated with a 63% reduction in acute bronchiolitis-related hospital admission.
Vaccines were most cost-effective when given to adults ages 70 and older who had chronic medical conditions.
Vaccine effectiveness was just as high among participants aged 75 years and older as it was in those 60 and older.
